ARS Pharmaceuticals (SPRY) said the US Food and Drug Administration approved a lower dosage of neffy for allergic emergencies, including anaphylaxis.
The regulator approved a 1 milligram version of the nasal spray for children 4 years and up, the company said Wednesday in a statement.
A 2 mg version of neffy, an epinephrine nasal spray, was approved in the US in 2024.
ARS shares rose 5.1% in after-hours trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。